Virtual 2020 BioHealth Capital Region Forum

Top 3 by 2023

SAVE THE DATE! October 19, 2020


20% of the top influencers worldwide in vaccine development


World-class tech + big data + biotech + White House Precision Medicine Initiative = new frontiers in patient-centered medicine


MD | DC | VA

Our Goal: To become a Top 3 BioHealth Hub by 2023.

We are the research engine for the nation and the world. A lifeblood of support for taking new medicines to market. A place where health policymakers and patient advocates seek a better way forward. A home to the established and the startup, pioneering big ideas for human health and hope.

Driving Innovation and Entrepreneurship

  • World–renowned research institutions and universities
  • Influential policymakers and advocacy groups pioneering new health strategies
  • World–leading infectious disease research and vaccine development
  • Fastest growing region for healthcare companies in the U.S.
  • Rated #1 in the nation for science and engineering talent
  • Mission control for the National Cancer Moonshot Initiative

Founding Partners

FDA Approves American Gene Technologies (AGT) to Move Forward with Phase 1 Clinical Trial of HIV Cure Program

August 11, 2020

Published: Aug 11, 2020 ROCKVILLE, Md., Aug. 11, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT) announced today approval by the Food and Drug Administration (FDA) to begin Phase 1, the first human clinical trial…

USM Maryland Momentum Fund Invests $250,000 in $3.5M Seed Round of miRecule Inc.

August 10, 2020

Baltimore, MD. (Aug. 10, 2020) — The University System of Maryland (USM) Momentum Fund has invested $250K in miRecule, an emerging biotech company with a cutting-edge discovery platform to create RNA…

BioForward Wisconsin’s Lisa Johnson Virtually joins Rich Bendis on BioTalk

August 10, 2020

The BioHealth Capital Region and BioForward Wisconsin come together as Lisa Johnson joins Rich Bendis on BioTalk to discuss her career, the industry, and growing biohealth in the Midwest. Listen…

Altimmune Completes Enrollment In Phase 1b Clinical Trial Of NasoShield™, A Single Dose Intranasal Anthrax Vaccine Candidate

August 7, 2020

GAITHERSBURG, Md., Aug. 07, 2020 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment in its Phase 1b clinical trial of NasoShield, a single dose…

Adaptive Phage Therapeutics Announces Mayo Clinic as Lead Investor in Convertible Note Financing

August 5, 2020

GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced Mayo…

REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD

August 4, 2020

ROCKVILLE, Md., Aug. 4, 2020 /PRNewswire/ — Company on track to initiate RGX-314 subretinal delivery pivotal program by the end of 2020 RGX-314 was generally well-tolerated in 42 patients at all dose…